Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study.
作者信息
Sachs E, Di Bisceglie A M, Dusheiko G M, Song E, Lyons S F, Schoub B D, Kew M C
出版信息
Br J Cancer. 1985 Jul;52(1):105-9. doi: 10.1038/bjc.1985.156.
Abstract
摘要
相似文献
1
Treatment of hepatocellular carcinoma with recombinant leucocyte interferon: a pilot study.重组白细胞干扰素治疗肝细胞癌的初步研究。
Br J Cancer. 1985 Jul;52(1):105-9. doi: 10.1038/bjc.1985.156.
2
A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma. The Gastrointestinal Tumor Study Group.
Cancer. 1990 Jul 1;66(1):135-9. doi: 10.1002/1097-0142(19900701)66:1<135::aid-cncr2820660124>3.0.co;2-7.
3
Oral gamma-linolenic acid in 21 patients with untreatable malignancy. An ongoing pilot open clinical trial.
Br J Clin Pract. 1987 Sep;41(9):907-15.
4
Interferon for postresection recurrence of hepatocellular carcinoma.
Am J Gastroenterol. 2002 Dec;97(12):3200-2. doi: 10.1111/j.1572-0241.2002.07133.x.
5
Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.重组α2干扰素治疗无法手术的肝细胞癌优于阿霉素：一项前瞻性随机试验
Br J Cancer. 1989 Dec;60(6):928-33. doi: 10.1038/bjc.1989.392.
6
[Basic and clinical study of interferon a in hepatocellular carcinoma].
Zhonghua Wai Ke Za Zhi. 2008 Nov 1;46(21):1606-8.
7
Adjuvant interferon for hepatocellular carcinoma.
Hepatology. 2001 Feb;33(2):481-2. doi: 10.1002/hep.510330227.
8
Sunitinib and the benefits of a negative study.舒尼替尼与阴性研究的益处。
Lancet Oncol. 2009 Aug;10(8):743-4. doi: 10.1016/S1470-2045(09)70206-2.
9
The use of interferon functional assays in the laboratory monitoring of patients with hepatocellular carcinoma receiving interferon.
Am J Clin Pathol. 1986 Apr;85(4):450-5. doi: 10.1093/ajcp/85.4.450.
10
Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.低丙型肝炎病毒核糖核酸水平的肝细胞癌患者的干扰素治疗
Hepatogastroenterology. 2002 May-Jun;49(45):724-9.
引用本文的文献
1
Hepatocellular carcinoma.肝细胞癌
Postgrad Med J. 2000 Jan;76(891):4-11. doi: 10.1136/pmj.76.891.4.
2
Sodium butyrate enhances STAT 1 expression in PLC/PRF/5 hepatoma cells and augments their responsiveness to interferon-alpha.丁酸钠可增强PLC/PRF/5肝癌细胞中STAT 1的表达，并增强其对α干扰素的反应性。
Br J Cancer. 1999 May;80(5-6):705-10. doi: 10.1038/sj.bjc.6690413.
3
Practical considerations in the treatment of hepatocellular carcinoma.肝细胞癌治疗中的实际考量
Drugs. 1998 Mar;55(3):367-82. doi: 10.2165/00003495-199855030-00004.
4
Rapid growth of hepatocellular carcinoma after or during interferon treatment of chronic hepatitis C: report of three cases.
Surg Today. 1996;26(2):126-30. doi: 10.1007/BF00311777.
5
Current treatment modalities for hepatocellular carcinoma.肝细胞癌的当前治疗方式。
Ann Surg. 1994 Mar;219(3):236-47. doi: 10.1097/00000658-199403000-00003.
6
Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results.肝动脉内联合免疫化疗治疗不可切除肝细胞癌：初步结果
Cancer Immunol Immunother. 1994 Mar;38(3):194-200. doi: 10.1007/BF01525641.
7
No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.表柔比星与α-2b干扰素联合治疗肝细胞癌无协同活性。
Cancer Chemother Pharmacol. 1995;35(4):334-8. doi: 10.1007/BF00689454.
8
Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon alpha gene therapy in combination with adoptive chemoimmunotherapy.成纤维细胞介导的人α干扰素基因治疗联合过继性化学免疫疗法治疗人肝细胞癌
J Cancer Res Clin Oncol. 1995;121(8):457-62. doi: 10.1007/BF01218361.
9
Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial.重组α2干扰素治疗无法手术的肝细胞癌优于阿霉素：一项前瞻性随机试验
Br J Cancer. 1989 Dec;60(6):928-33. doi: 10.1038/bjc.1989.392.
本文引用的文献
1
The hepatitis-B virus and hepatocellular carcinoma.乙型肝炎病毒与肝细胞癌
Semin Liver Dis. 1981 Feb;1(1):59-67. doi: 10.1055/s-2008-1063930.
2
Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus.干扰素和自然杀伤细胞在裸鼠中对抑制感染乙型肝炎病毒的人肝癌细胞致瘤性的作用。
J Clin Invest. 1983 Aug;72(2):707-17. doi: 10.1172/jci111020.
3
The clinical value of interferons as antitumor agents.
Eur J Cancer Clin Oncol. 1981 Sep;17(9):949-67. doi: 10.1016/s0277-5379(81)80001-6.
4
Tumorigenicity and interferon properties of the PLC/PRF/5 human hepatoma cell line.
Prog Med Virol. 1981;27:103-8.
Zotero 插件